Specifically, patients using GLP-1 receptor agonists exhibited a lower risk of esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancers, as well as meningioma and multiple myeloma [3]. Here, GLP1R is linked to plasma cell myeloma.